Physician profile
Michael D Evans
NPI 1689678187
$1,951.10
in general payments reported to CMS, 2019-2025
17 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $44.61 · 2021: $369 · 2022: $370 · 2023: $377 · 2024: $112 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,162.88 | 2019-2025 | Gallant, Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx |
| Microtransponder, INC. | $132.84 | 2025 | |
| Inari Medical, INC. | $124.17 | 2021 | |
| Inspire Medical Systems, INC. | $107.99 | 2025 | Inspire |
| Impulse Dynamics (USA) INC. | $50.92 | 2025 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $50.18 | 2024-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.96 | 2023-2025 | Lifevest |
| Silk Road Medical, INC. | $47.62 | 2020-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Abiomed | $41.20 | 2025 | |
| Amarin Pharma, INC. | $39.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.48 | 2024 | |
| Novo Nordisk INC | $24.11 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $23.84 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $17.49 | 2023 | Farxiga |
| Medtronic Vascular, INC. | $15.85 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12.84 | 2019 | |
| Gilead Sciences, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.